Goldman Sachs raises target to USD 4.00 for Rocket Pharmaceuticals stock

Published on 10/15/2026 at 22:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Twelve analysts set a USD 7.77 consensus target on October 15, 2026. Rocket Pharmaceuticals stock costs EUR 2.10 on October 15, 2026 at 10:27 p.m. CEST.

Analyst views and market measures

On October 8, 2026, Goldman Sachs lifted its Rocket Pharmaceuticals target to USD 4.00.
Twelve analysts had a consensus target of USD 7.77 on October 15, 2026.
Rocket Pharmaceuticals stock costs EUR 2.10 at Lang & Schwarz on October 15, 2026 at 10:27 p.m. CEST.
Market capitalization stood at USD 259.1 million and the P/E ratio was minus 13.88 on October 15, 2026.

RCKT, US77313F1066, Illustration mit AI erstellt.

Goldman Sachs upgraded Rocket Pharmaceuticals and lifted its price target from USD 3.00 to USD 4.00 on October 8, 2026, a 69.49 percent premium to the latest USD 2.36 Nasdaq quote. According to Yahoo Finance, the firm also upgraded its rating from Sell to Neutral.

Consensus target remains higher

The broader analyst picture points to a higher valuation reference. TranscriptDaily reported on October 15, 2026 that 12 analysts had an average 12-month target of USD 7.77. The figure is 94.49 percent above USD 4.00, the latest Goldman Sachs target.

Range and trading activity

Rocket Pharmaceuticals traded within a USD 2.18 to USD 5.45 52-week range as of October 15, 2026. The USD 2.36 latest Nasdaq quote stood USD 0.18, or 8.26 percent, above the range low and USD 3.09, or 56.70 percent, below the high.

Trading volume for the latest quoted session was 1,878,183 shares against an average of 1,752,096 shares. That places activity 7.19 percent above the average, while the market capitalization stood at USD 259.1 million.

Valuation and company profile

The company remains a loss-making biotechnology developer. Its P/E ratio was minus 13.88 on October 15, 2026, and it paid no dividend. MarketBeat describes Rocket Pharmaceuticals as a Nasdaq-listed biotechnology company developing gene therapies for rare diseases.

Comparison with peers

Rocket Pharmaceuticals (Nasdaq, USD): P/E minus 13.88, market capitalization USD 259.1 million, October 15, 2026.

Editas Medicine (Nasdaq, USD): plus 7.49 percent, P/E minus 3.26, market capitalization USD 374.7 million, October 15, 2026.

CRISPR Therapeutics (Nasdaq, USD): plus 2.59 percent, P/E minus 10.82, market capitalization USD 5.0 billion, October 15, 2026.

Rocket Pharmaceuticals price snapshot

Rocket Pharmaceuticals was trading at EUR 2.10 at Lang & Schwarz on October 15, 2026 at 10:27 p.m. CEST. The latest euro quote provides the market frame, while analyst targets remain stated in USD and refer to the Nasdaq listing.

The further course of trading is shown by the continuously updated real-time quote of Rocket Pharmaceuticals stock.